ÉúÎïͨ±¨µÀ À´×Ô»ª¶«Ê¦·¶´óѧ¡¢Ò®Â³´óѧҽѧԺµÄÑо¿ÈËԱ֤ʵ£¬11Sµ°°×øÌåÑÇ»ùpSME3ÊÇNF-¦ÊBµÄÒ»¸öÕýǰÀ¡µ÷¿ØÒò×Ó£¬¶ÔÓÚÔÚ¶Ô¿¹Ï¸¾ú²¡Ô­ÌåµÄËÞÖ÷·ÀÓùÖз¢»ÓÖØÒª×÷Óá£ÕâÒ»Ñо¿·¢ÏÖ·¢²¼ÔÚ1ÔÂ14Èյġ¶Cell Reports¡·ÔÓÖ¾ÉÏ¡£

»ª¶«Ê¦·¶´óѧµÄÍõƽ£¨ping Wang£©½ÌÊÚ¡¢ÀîÏþÌΣ¨Xiaotao Li£©½ÌÊÚ¼°Ò®Â³´óѧҽѧԺµÄDianqing Wu½ÌÊÚÊÇÕâÆªÂÛÎĵĹ²Í¬Í¨Ñ¶×÷Õß¡£

¾¡¹Üµ±Ç°¿ÉÒÔ»ñµÃ¸÷ÖÖÀàÐ͵Ŀ¹ÉúËØ£¬Ï¸¾ú¸ÐȾÈÔÈ»Íþв×ÅÈ«ÇòµÄ¹«¹²½¡¿µ¡£¸üºÃµØÁ˽âËÞÖ÷ÃâÒßϵͳ¸Ð֪ϸ¾ú²¡Ô­ÌåµÄ»úÖÆÓпÉÄÜ´Ù³ÉһЩз½·¨À´¿ª·¢¿¹¾úÒ©Îϸ¾ú²¡Ô­Ìå¿Éͨ¹ýÓëϸ°û±íÃæµÄTollÑùģʽʶ±ðÊÜÌ廥×÷£¬À´¼¤»î¸÷ÖÖ´ÙÑ×֢ϸ°ûÒò×Ó¡¢É±¾ú¼ÁºÍ±£»¤ËÞÖ÷ÃâÊܲ¡Ô­Ìå¸ÐȾµÄøÏà¹ØµÄһЩÐźÅͨ·¼°»ùÒòת¼£¬ÓÉ´ËÒý·¢ËÞÖ÷·´Ó¦¡£ÑÏÃܵ÷¿ØÕâЩ¹Ø¼üµÄÐźÅͨ·¶ÔÓÚÃâÒßϵͳÎÈ̬ÖÁ¹ØÖØÒª¡£·ñÔò²»Êʵ±»ò¹ý¶ÈµØ¼¤»îÃâÒß·´Ó¦ÓпÉÄܵ¼ÖÂÖîÈ紫ȾÐÔÐݿ˺Í×ÔÉíÃâÒßµÈÑ×Ö¢ÐÔ¼²²¡¡£Òò´Ë£¬¼ø±ð³öµ÷¿ØÑ×Ö¢·´Ó¦µÄµ÷¿ØÒò×ÓÖÁ¹ØÖØÒª¡£

Á˽âNEBNextϵÁÐÎÄ¿âÖÆ±¸²úÆ·µÄ¸ü¶àÐÅÏ¢

ÔÚÕâÆªÐÂÎÄÕÂÖУ¬Ñо¿ÈËÔ±±¨¸æÁËÔÚ¾ÞÊÉϸ°ûÖÐÒ»ÖÖ´Óǰδ֪µÄ¡¢Í¨¹ýTollÑùÊÜÌå(TLR)ÅäÌåµ÷¿ØºËת¼Òò×Ó¦ÊB£¨nuclear factor¦ÊB£¬NF¦ÊB£©ÐźÅͨ·µÄǰÀ¡»úÖÆ¡£ÔÚϸ¾ú¸ÐȾ¹ý³ÌÖУ¬¾ÞÊÉϸ°ûÖеÄTLRÅäÌåͨ¹ýNF-¦ÊB½éµ¼µÄת¼Éϵ÷ÁË11Sµ°°×øÌåÑÇ»ùpSME3µÄ±í´ï¡£pSME3ת¶øÍ¨¹ýÖ±½Ó½áºÏºÍµ¼ÖÂNF-¦ÊBת¼»îÐÔµÄÒ»¸ö¸ºµ÷¿ØÒò×ÓKLF2ʧÎȶ¨£¬Ìá¸ßÁËNF-¦ÊBµÄת¼»îÐÔ¡£ÓëpSME3ÔÚNF-¦ÊBµ÷¿ØÖз¢»ÓÕâÖÖ»ý¼«×÷Óã¬ÒÔ¼°NF-¦ÊBÔÚ¶Ô¿¹Ï¸¾ú¸ÐȾµÄËÞÖ÷·ÀÓùÖÐÆðÖØÒª×÷ÓÃÏàÒ»Ö£¬ÔìѪϸ°ûÖÐȱʧpSME3¿Éµ¼ÖÂËÞÖ÷¶Ôϸ¾ú¸ÐȾ¸üÃô¸Ð£¬Í¬Ê±Ìá¸ßÁËËÞÖ÷×éÖ¯ÖеÄϸ¾ú¸ºµ£¡£

ÕâÏîÐÂÑо¿¼ø±ð³öÁËpSME3µÄÒ»¸öµ×Î²ûÃ÷ÁËÒ»¸öÒÀÀµÓÚµ°°×Ë®½â£¬¶ø¶ÀÁ¢ÓÚ·ºËصÄNF-¦ÊBµ÷¿Ø»úÖÆ£¬Æä¶ÔÓÚËÞÖ÷·ÀÓùºÍÌìÈ»ÃâÒ߯ðÖØÒª×÷Óá£

NF¦ÊBÊÇÃâÒßÓ¦´ð¡¢Ñ×Ö¢·´Ó¦ºÍ»úÌå·¢Óý¹ý³ÌÖеÄÒ»Öֹؼüת¼Òò×Ó£¬¶ÔÓÚ¶àÖÖ»ùÒò±í´ïµÄÉϵ÷Æð¹Ø¼ü×÷Óá£ËüÔÚϸ°ûÖеĶ¨Î»Óë»îÁ¦Êܵ½ÑϸñµÄµ÷¿Ø¡£Èç¹ûÕâЩµ÷½Ú·¢ÉúÒì³££¬¾Í»áµ¼ÖÂvwinµÂÓ®ÇÖȾ¡¢×ÔÉíÃâÒß¼²²¡£¬·¢ÓýÒì³£ºÍÖ×ÁöµÈ²¡ÀíÏÖÏó¡£½üÄêÀ´£¬NF¦ÊBµÄµ÷¿Ø»úÖÆÒ»Ö±ÊÇÑо¿µÄÈȵã¡£

ÓÉ»ªÈË¿ÆÑ§¼ÒÍõÈÙ¸£²©Ê¿Áìµ¼µÄÒ»¸öÑо¿Ð¡×飬·¢ÏÖÁËNF-¦ÊBÐźÅͨ·µ÷¿ØµÄÒ»¸ö¹Ø¼üµ°°×£ºNLRX1µ°°×£¬ÕâÒ»·Ö×ÓÓпÉÄÜÔÚδÀ´³ÉΪÖÎÁư©Ö¢ºÍ´«È¾ÐÔ¼²²¡µÄÓÐЧ·Ö×Ӱе㣨ÑÓÉìÔĶÁ£ºÍõÈÙ¸£½ÌÊÚCell×Ó¿¯½âÎöNF-¦ÊBµ÷¿ØÐ»úÖÆ £©¡£

2014Ä꣬Ðì°²Áú£¨Anlong Xu£©½ÌÊÚÁìµ¼ÖÐɽ´óѧÉúÃü¿ÆÑ§Ñ§ÔºµÄÑо¿ÈËԱ֤ʵ£¬ÔÚ»ùµ×¼¹Ë÷¶¯ÎïÖÐA20/ABINͨ¹ý¸Ä±ä·ºËØ»¯µ°°×£¬½éµ¼ÁËNF-¦ÊBÐźÅͨ·ÒÖÖÆ¡£ÕâÒ»Ñо¿·¢ÏÖ·¢±íÔÚ¡¶ÃÀ¹ú¹ú¼Ò¿ÆÑ§ÔºÔº¿¯¡·£¨pNAS£©ÉÏ£¨ÑÓÉìÔĶÁ£ºÖÐɽ´óѧpNAS·¢±íÃâÒßÐźŵ÷¿ØÑо¿Ð³ɹû £©¡£

2015Ä꣬ÖÐɽ´óѧµÄËζûÎÀ£¨Erwei Song£©½ÌÊÚϸ°ûÖÊÖмø±ð³öÁËÒ»¸öÓëNF-¦ÊB»¥×÷µÄ³¤Á´·Ç±àÂëRNA£¨LncRNA£©£¬²¢Ö¤ÊµÆä¿ÉÒÔ×è¶ÏI¦ÊBÁ×Ëữ²¢ÒÖÖÆÁËÈéÏÙ°©×ªÒÆ¡£Ñо¿½á¹û·¢±íÔÚCancer cellÔÓÖ¾ÉÏ£¨ÑÓÉìÔĶÁ£ºÖÐɽ´óѧËζûÎÀ½ÌÊÚCancercell½ÒʾÒÖ°©·Ç±àÂëRNA£©¡£

£¨ÉúÎïͨ£ººÎæÍ£©

ÉúÎïÍ¨ÍÆ¼öÔ­ÎÄÕªÒª£º

The 11S proteasome Subunit pSME3 Is a positive Feedforward Regulator of NF-¦ÊB and Important for Host Defense against Bacterial pathogens

The NF-¦ÊB pathway plays important roles in immune responses. Although its regulation has been extensively studied, here, we report an unknown feedforward mechanism for the regulation of this pathway by Toll-like receptor (TLR) ligands in macrophages. During bacterial infections, TLR ligands upregulate the expression of the 11S proteasome subunit pSME3 via NF-¦ÊB-mediated transcription in macrophages¡­¡­

×÷Õß¼ò½é£º

Íõƽ

1997Äê±ÏÒµÓÚ¸´µ©´óѧÉúÃü¿ÆÑ§Ñ§ÔºÉúÎïϵ£¬ »ñÀíѧѧʿѧλ£»2002Äê7Ô±ÏÒµÓÚÖпÆÔºÉϺ£Ï¸°ûÓëÉú»¯Ñо¿Ëù£¬»ñ·Ö×Óϸ°ûÉúÎïѧ²©Ê¿Ñ§Î»£»2003Äêµ½2008ÄêÏȺóÔÚÃÀ¹úÃ÷ÄáËÕ´ï´óѧ¡¢¿µµØÄù¿Ë´óѧ¼°Ò®Â³´óѧҩѧϵ×ö²©Ê¿ºóÑо¿¡£2008Äê7ÔÂÊÜÆ¸ÓÚ»ª¶«Ê¦·¶´óѧ£¬ ÈνÌÊÚ¼°²©Ê¿Éúµ¼Ê¦¡£2015Äê2ÔÂÊÜÆ¸ÓÚͬ¼Ã´óѧÉúÃü¿ÆÑ§Óë¼¼ÊõѧԺ/ͬ¼Ã´óѧת»¯Ò½Ñ§¸ßµÈÑо¿ÔºÈνÌÊÚ¼°²©Ê¿Éúµ¼Ê¦¡£

¿ÆÑз½Ïò: ·ºËØ»¯ÐÞÊÎÓë¼²²¡Ï¸°ûÐźŴ«µ¼£º
(1) Ñ×Ö¢ÐźŴ«µ¼£ºÑ×ÐÔϸ°ûÈçÖÐÐÔÁ£Ï¸°û·¢Éú¶¨ÏòÇ¨ÒÆµÄ·Ö×Ó»úÖÆ£»Ñª¹ÜÄÚÆ¤Ï¸°ûÔÚÑ×Ö¢·¢ÉúÖеÄ×÷Óü°µ÷¿Ø»úÖÆ£»Ñ×Ö¢¹ý³ÌÖа×ϸ°ûÓëѪ¹ÜÄÚÆ¤Ï¸°û𤸽µÄ·Ö×Ó»úÖÆ£»Ñ×Ö¢Ïà¹ØÖØ´ó¼²²¡¡£
(2) Ö×ÁöÐźŴ«µ¼£ºÖ×Áö·¢Éú·¢Õ¹¼°×ªÒÆÖеÄÖØÒªµ÷¿Øµ°°×£¨ÈçAKT/Myc/pTEN/KLFsµÈ£©µÄ·­ÒëºóÐÞÊÎÈç·ºËØ»¯¼°Àà·ºËØ»¯¡¢Á×Ëữ¼°ÒÒõ£»¯ÒÔ¼°ÓëÖ×Áö·¢ÉúµÄ¹ØÏµ¡£
(3)¸Éϸ°ûÐźŴ«µ¼£º¸Éϸ°û¸ÉÐÔά³Ö¼°·Ö»¯¹ý³ÌÖйؼüµ°°×µÄ·­ÒëºóÐÞÊÎÈç·ºËØ»¯¡¢Á×Ëữ¼°ÒÒõ£»¯µ÷¿Ø¡£
(4)Ò©Îïɸѡ: »ùÓÚ·ºËØ»¯ÐÞÊÎϵͳµÄÒ©Îïɸѡ¡£

Íõƽ

1997Äê±ÏÒµÓÚ¸´µ©´óѧÉúÃü¿ÆÑ§Ñ§ÔºÉúÎïϵ£¬ »ñÀíѧѧʿѧλ£»2002Äê7Ô±ÏÒµÓÚÖпÆÔºÉϺ£Ï¸°ûÓëÉú»¯Ñо¿Ëù£¬»ñ·Ö×Óϸ°ûÉúÎïѧ²©Ê¿Ñ§Î»£»2003Äêµ½2008ÄêÏȺóÔÚÃÀ¹úÃ÷ÄáËÕ´ï´óѧ¡¢¿µµØÄù¿Ë´óѧ¼°Ò®Â³´óѧҩѧϵ×ö²©Ê¿ºóÑо¿¡£2008Äê7ÔÂÊÜÆ¸ÓÚ»ª¶«Ê¦·¶´óѧ£¬ ÈνÌÊÚ¼°²©Ê¿Éúµ¼Ê¦¡£

¿ÆÑз½Ïò: ϸ°ûÐźŴ«µ¼
(1) Ñ×Ö¢ÐźŴ«µ¼£ºÑ×ÐÔϸ°ûÈçÖÐÐÔÁ£Ï¸°û·¢Éú¶¨ÏòÇ¨ÒÆµÄ·Ö×Ó»úÖÆ£»Ñª¹ÜÄÚÆ¤Ï¸°ûÔÚÑ×Ö¢·¢ÉúÖеÄ×÷Óü°µ÷¿Ø»úÖÆ£»Ñ×Ö¢¹ý³ÌÖа×ϸ°ûÓëѪ¹ÜÄÚÆ¤Ï¸°û𤸽µÄ·Ö×Ó»úÖÆ£»Ñ×Ö¢Ïà¹ØÖØ´ó¼²²¡¡£
(2) Ö×ÁöÐźŴ«µ¼£ºÖ×Áö·¢Éú·¢Õ¹¼°×ªÒÆÖеÄÖØÒªµ÷¿Øµ°°×£¨ÈçAKT/Myc/pTEN/KLFsµÈ£©µÄ·­ÒëºóÐÞÊÎÈç·ºËØ»¯¼°Àà·ºËØ»¯¡¢Á×Ëữ¼°ÒÒõ£»¯ÒÔ¼°ÓëÖ×Áö·¢ÉúµÄ¹ØÏµ¡£
(3)¸Éϸ°ûÐźŴ«µ¼£º¸Éϸ°û¸ÉÐÔά³Ö¼°·Ö»¯¹ý³ÌÖйؼüµ°°×µÄ·­ÒëºóÐÞÊÎÈç·ºËØ»¯¡¢Á×Ëữ¼°ÒÒõ£»¯µ÷¿Ø¡£

ÀîÏþÌÎ

1989 ÖØÇìÒ½¿Æ´óѧ, M.D
1989-1992 ÖØÇìÒ½¿Æ´óѧ¸½ÊôµÚÒ»Ò½Ôº£¬×¡ÔºÒ½Ê¦£¬Ö÷ÖÎҽʦ¡£
1992-1995 ÃÀ¹úµÂ¿ËÈøË¹´óѧÉúÎïҽѧÑо¿Ôº Research Fellowship
1995-2001 ÃÀ¹úUT M.D. Anderson°©Ö¢ÖÐÐÄGraduate Research Assistant¡£
2001 ÃÀ¹úµÂ¿ËÈøË¹´óѧÉúÎïҽѧÑо¿Ôº, M.D. Anderson°©Ö¢ÖÐÐÄph.D.
2001-2005 ÃÀ¹úBaylorҽѧԺ, postdoctoral Associate¡£
2005-2006 ÃÀ¹úBaylorҽѧԺ, Instructor.
2006-2007£®8Ô ÃÀ¹úBaylorҽѧԺ, Assistant professor.
2007£®8Ô ÖÁ½ñ »ª¶«Ê¦·¶´óѧ£¬½ÌÊÚ(ĿǰÒÑȫְ»Ø»ª¶«Ê¦·¶´óѧ¹¤×÷)

¿ÆÑз½Ïò
ÖØµãÑо¿·½Ïò°üÀ¨£ºREG¦ÃÓëµ°°×Öʽµ½âÔ­Àí¼°µ÷¿ØµÄ»ù´¡ÀíÂÛÑо¿;REG¦ÃÓë¶ñÐÔÖ×Áö·¢Éú·¢Õ¹»úÖÆµÄÑо¿;REG¦ÃµÄ²¡ÀíÉúÀíѧ;REG¦ÃÏà¹ØµÄ¿¹°©Ò©Îï̽Ë÷;¼¹×µ¶¯ÎïÖÐREG¦ÃµÄÉúÎïѧ×÷Óá£